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Consensus-Based Recommendations on Priority Activities
to Address Acute Kidney Injury in Children
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Abstract
IMPORTANCE Increasing evidence indicates that acute kidney injury (AKI) occurs frequently in
children and young adults and is associated with poor short-term and long-term outcomes. Guidance
is required to focus efforts related to expansion of pediatric AKI knowledge.

Key Points
Question What are the clinical care,
education, research and advocacybased priorities for acute kidney injury
(AKI) in children and young adults?

OBJECTIVE To develop expert-driven pediatric specific recommendations on needed AKI research,

Findings In this consensus statement, a

education, practice, and advocacy.

panel of 46 global experts developed
pediatric AKI specific consensus

EVIDENCE REVIEW At the 26th Acute Disease Quality Initiative meeting conducted in November

statements regarding epidemiology,

2021 by 47 multiprofessional international experts in general pediatrics, nephrology, and critical care,

diagnostics, mechanical support,

the panel focused on 6 areas: (1) epidemiology; (2) diagnostics; (3) fluid overload; (4) kidney support

educational goals, and biologic and

therapies; (5) biology, pharmacology, and nutrition; and (6) education and advocacy. An objective

physiologic development of the growing

scientific review and distillation of literature through September 2021 was performed of (1)

child. In addition gaps in knowledge and

epidemiology, (2) risk assessment and diagnosis, (3) fluid assessment, (4) kidney support and

areas for further research were

extracorporeal therapies, (5) pathobiology, nutrition, and pharmacology, and (6) education and

identified.

advocacy. Using an established modified Delphi process based on existing data, workgroups derived
consensus statements with recommendations.

Meaning Focused and coordinated
efforts, integrating AKI specialists and
researchers with the general medical

FINDINGS The meeting developed 12 consensus statements and 29 research recommendations.
Principal suggestions were to address gaps of knowledge by including data from varying
socioeconomic groups, broadening definition of AKI phenotypes, adjudicating fluid balance by
disease severity, integrating biopathology of child growth and development, and partnering with
families and communities in AKI advocacy.

community and population, may
improve short-term and long-term
outcomes for children and young adults
with AKI in the areas of disease
awareness, diagnostics, recognition,
management, and follow-up.

CONCLUSIONS AND RELEVANCE Existing evidence across observational study supports further
efforts to increase knowledge related to AKI in childhood. Significant gaps of knowledge may be
addressed by focused efforts.
JAMA Network Open. 2022;5(9):e2229442.
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Introduction
The pediatric acute kidney injury (AKI) research field has expanded during the past decade with
international epidemiologic studies, long-term AKI follow-up studies, validation of AKI prediction
models, and continued investigation of novel AKI biomarkers.1-9 The 26th Acute Disease Quality
Initiative (ADQI XXVI) convened in Napa, California, in November 2021, the first Pediatric ADQI
(pADQI) that specifically addressed the global burden of AKI in the child and young adult population,
with focused attention paid to kidney development and AKI, prenatal or neonatal kidney physiology,
dialysis devices engineered for children,10 and the unique aspects of pediatric AKI epidemiology. The
pADQI was assembled to mirror the global workforce in pediatrics and used a public and patientfacing approach. The primary aim of the pADQI was to identify the work priorities across the pediatric
AKI landscape of care, education, research, and advocacy.

Methods
The pADQI consensus meeting followed the established ADQI process, as previously described,11 to
provide expert-based statements and interpretation of current knowledge for use by clinicians
according to professional judgment and identify evidence care gaps to establish research priorities.
We performed an objective scientific review and distillation of literature through September 2021 of
(1) epidemiology, (2) risk assessment and diagnosis, (3) fluid assessment, (4) kidney support and
extracorporeal therapies, (5) pathobiology, nutrition, and pharmacology, and (6) education and
advocacy. The 6 workgroups were composed of representatives from 5 continents of varying age
(median: 43 years; range, 24-74 years), gender (23 male, 23 female) and professional discipline
(physicians, nurses, pharmacists, and nutritionists). In addition, a pediatric patient survivor of AKI
and an expert in equity and care delivery were included in the pADQI and assisted all workgroups.
The in-person meeting was conducted using workgroups and large group in mixed in-person and
virtual (72% in person) formats. Work following the in-person meeting was completed virtually.
Using a modified Delphi method, each workgroup determined key questions supported by
representative literature, or professional opinion when evidence was scarce, and presented their
drafts iteratively to develop consensus statements (target of 2-3 per group) (main document), and to
articulate a research agenda with a more comprehensive background (Table; eBackground and eBox
in the Supplement). The consensus statements were categorized as recommendations or
suggestions. The work product was finalized and approved by the entire group in 2 follow-up
web-based meetings. This summary statement was based on existing evidence in the literature, thus
institutional approval was not required. All members of pADQI consented to their inclusion in this
article. The statements are presented herein as direct quotations.

Table. Consensus-Derived Considerations to Address Knowledge Gaps for Children and Young Adults With Acute Kidney Injury
Paradigm

Consensus

Knowledge gap and needed work

Epidemiology

• Stratified understanding of high risk:
Neonates, heart disease, chronic kidney disease, sepsis, cystic fibrosis, transplant history,
oncologic history, chronic liver disease

• Middle- and low-income populations
• Expanded AKI phenotypes

Diagnostics

• Biomarker-based delineation of standard vs high risk

• Integration of concurrent diagnostics
• Differentiation of diagnostics over time

Fluid balance

• Use of percent fluid balance and anchor weight (ICU admission weight)

• Adjudicate “fluid overload” by illness state

KST

• Institute benchmarks and components of KST team
• Need for pediatric specific extracorporeal therapies

• KST team, quality, and cost optimization
• KST integration of tandem therapies

Biopathology

• Pediatrics incorporated into research efforts
• Importance of nephrotoxin stewardship programs
• Promoting bench-bedside collaboration between preclinical, epidemiological
and clinical trial researchers

• Determination of sex as a biological variable related to AKI
• Characterize medications affected by AKI across
developmental spectrum
• Identify the optimal nutritional interventions by age for
AKI

Education and
advocacy

• Differential approach based on national resources
• Integration of electronic medical record/checklists

• Governmental and community partnerships
• Cross-discipline health care training

Abbreviations: AKI, acute kidney injury; ICU, intensive care unit; KST, kidney support therapy.
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The age spectrum of patients receiving the care of pediatric specialists ranged from extremely
low birthweight neonates to young adults. Throughout this manuscript, the terms child, children, and
pediatric reflect the entire age spectrum, unless specifically noted.

Group 1: What Will Drive the Continuing Refinement and Evolution
ofAKI Epidemiology?
Consensus Statement 1A (Recommendation)
• AKI epidemiology related to short-term outcomes is well-described in critically ill neonates and
children from high-income countries; however, further study is needed in other health care
contexts, such as low-middle income countries and in non-ICU and ambulatory settings and for
socioeconomic and long-term outcomes.
Consensus Statement 1B (Suggestion)
• An understanding of pediatric AKI epidemiology allows us to begin employing strategies to improve
primary, secondary, and tertiary AKI prevention in at-risk patient groups.
Implementation of standardized criteria to define the presence and severity of AKI has facilitated a
description of pediatric AKI epidemiology.11-14 Prospective multicenter studies provide insight into
the epidemiology of AKI in critically ill neonates and children.1,2 Other studies describe AKI
epidemiology in specific cohorts of children including sepsis,15 those receiving nephrotoxins,16 and
cardiac surgical populations.17,18 However, residual knowledge gaps remain regarding the accurate
description of AKI epidemiology in other health care contexts as the most data come from highincome countries, and few studies have described AKI epidemiology outside critical care settings.
Pediatric literature has described AKI and morbidity, mortality, and health resource use in
critically ill children with a gradient-response association between AKI severity and the risk of worse
outcomes.1,19,20 More recently, research has focused on assessing the medium and long-term
sequalae of AKI, including longitudinal kidney function and its socioeconomic outcomes.16,21,22
A comprehensive description of pediatric AKI epidemiology reflects current practice and best
available information (eFigure 1 in the Supplement). Given this, information should be up to date and
readily available to clinicians and institutions in real time. A risk prediction study23 and a randomized
clinical trial24 suggest a causal link between pediatric AKI and a limited scope of short-term
outcomes, supporting prevention and mitigation of pediatric AKI and its complications as targets for
improving outcomes. Pediatric AKI epidemiologic characteristics can be categorized as pre-event
(eg, risk factors, key drivers, and predictors), peri-event (eg, demographic characteristics and
etiology), and postevent (eg, outcomes and recovery). Studies of AKI epidemiology should explore
the temporal nature of AKI, health contexts (eg, populations and locations) in which AKI has been
inadequately described, and outcomes that are focused on patient, family, cost, and performance.
Thus, by following epidemiologic trends, clinicians can help focus efforts to enhance public health
surveillance, augment field investigations, clinical and preclinical studies, and further policy
development to promote child health (eBox and eBackground in the Supplement).

Group 2: What Are the Unique Considerations for AKI Risk Stratification and Diagnosis
in Children?
Consensus Statement 2A (Recommendation)
• Validated tools which incorporate patient characteristics and exposure and also interface with the
local health care environment should be utilized to estimate AKI risk in children, including
assessment of objective measures of kidney fitness in at-risk children prior to a predictable or
planned intervention.
Consensus Statement 2B (Suggestion)
• Unique AKI phenotypes in children may overlap and change over time. Differentiating AKI
phenotype(s) informs prognosis and has the potential to guide therapeutics.
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Previous studies1,25-28 identified baseline patient characteristics and exposures that place children at
increased risk for AKI, including but not limited to cancer therapy, cardiopulmonary bypass,
extracorporeal membrane oxygenation, major surgical procedures, and a high nephrotoxic
medication burden.1,26,29 Integrating diagnostic resources may optimize AKI risk assessment for
high-risk diagnoses (eg, by using point-of-care testing and automated algorithms) or exposures (eg,
by using the electronic medical record) could be updated continuously in real time30 (Figure 1A31).
Prior to a planned exposure associated with increased AKI risk, ascertainment of kidney fitness
using traditional measures of kidney function and damage, including serum creatinine and cystatin
C levels, and urine albumin or protein level can be used to direct comprehensive kidney protection
and surveillance and prevent AKI development.32 Preoperative values of candidate biomarkers may
have utility in predicting AKI after cardiac surgery in adults and children.33-35 Kidney functional
reserve values can predict postoperative AKI in adults.36 (Figure 1A31).
When available, biomarkers that indicate structural kidney injury may provide further insight
into AKI risk and phenotype.37 For example, structural biomarker concentration elevation in the
absence of functional biomarker elevation may indicate early kidney injury that is not readily
reversible. Conversely, functional biomarker elevation alone may be indicative of decreased effective
circulating volume and direct care toward restoration of volume. The terms functional AKI and
structural AKI, to supplant the terms pre-renal AKI and intrinsic AKI were first proposed by the ADQI
X Consensus Conference.38 Single center pediatric study and systematic reviews provide initial
validation of these concepts, with structural AKI being associated with worse outcomes than
functional AKI alone.39-41

Figure 1. Acute Kidney Injury (AKI) Risk Assessment and Dynamic Phenotyping
A AKI risk assessment

Risk assessment

Heterogeneous
population of children

B

Routine care
• Repeat risk assessment with clinical changes

Standard risk for AKI

• Patient factors
• Disease factors
• Event factors
• Renal fitness

Kidney-focused care
• Comprehensive kidney protection and surveillance
• Targeted biomarker measurement
• Informed clinical trial enrollment

High risk for AKI

Dynamic AKI phenotyping

Serum
creatinine
Biomarkers

Unknown
factors

Dynamic AKI
phenotypes

Urine
output

Fluid
overload

Ongoing
assessment

Prognostic implications

Timing

Big data

Therapeutic implications
Patient with
undifferentiated AKI

Diuretic
response

Patient with differentiated
AKI phenotypes

Duration
Severity

A, AKI risk assessment should occur in children with a potential kidney insult or any
clinical changes to stratify patients into those at standard or high risk for AKI such that
kidney-focused care can be implemented. B, Combined with individual susceptibility,
multiple elements contribute to discernible AKI phenotypes in affected children that

may have prognostic and therapeutic implications. Adapted from the 26th Acute Disease
Quality Initiative31 with permission. These are open access images distributed under the
terms of the Creative Commons Attribution License.
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Pediatric AKI is a heterogeneous disease with multiple etiologic factors, biochemical signatures,
and clinical manifestations. Expert consensus and emerging data support the view that these
elements combined with individual susceptibility contribute to unique, discernible AKI phenotypes
in children with AKI (Figure 1B31). In particular, evidence supports the use of clinical features such as
urine output,42,43 severity and duration of creatinine elevation,44,45 fluid overload,46 response to
loop diuretics,47,48 and tubular injury biomarkers,39,41 to refine AKI diagnosis and reveal unique
phenotypes. The concept of subclinical AKI is defined by an elevation in a urine tubular injury
biomarker without elevation in functional marker. Subclinical AKI is associated with worse outcomes
in children without AKI or with functional AKI.39,41 Although these studies examined static 1 or 2
factor-based AKI phenotypes, it is likely that more than 1 of these discernible phenotypes may be
present in a child with AKI at a given time and that this unique phenotypic signature is dynamic
(Figure 1B31). A dynamic diagnostic model to address a dynamic phenotype, akin to blood gas
assessment in acute lung injury, may be required for AKI (eBox and eBackground in the Supplement).

Group 3: What Considerations Are Needed for Fluid Assessment in Sick Children?
Consensus Statement 3A (Recommendation)
• Fluid balance is the difference between total input and output that can be expressed as “daily”
and/or “cumulative” over a defined duration of time.
Consensus Statement 3B (Suggestion)
• Fluid overload denotes a pathologic state of positive fluid balance associated with a clinically
observable event(s), which may vary by age, case-mix, acuity, and phase of illness. No specific
threshold of positive fluid balance alone can define fluid overload across all sick children.
As with AKI diagnosis, consistent use of consensus terminology is essential to further our
understanding of fluid management and outcomes. Many terms have been used imprecisely to
assess the impact of fluid volume on outcomes in sick children, including fluid balance, fluid
accumulation, and fluid overload. Fluid overload has been conflated to describe both the degree of
positive fluid balance within a patient and its association with adverse outcomes.49-55 Use of the
term in this manner introduces bias into research and clinical practice, as it presumes any degree of
positive fluid balance is synonymous with fluid overload and is therefore detrimental. Moreover, such
use presumes that net fluid removal and targeting negative fluid balance is beneficial. Fluid overload
is a distinct pathologic state of positive fluid balance with adverse consequences. Fluid balance is an
objective calculation using specific methods. We suggest that the term percent cumulative fluid
balance be used to describe the previously referred term, percent fluid overload,56 to separate the
pathologic state from specific calculations. The terms daily fluid balance, cumulative fluid balance,
and percent cumulative fluid balance describe fluid status of patients for purpose of clinical care and
research (eTable 1 in the Supplement) more precisely.
The 2 methods most used to describe fluid balance are calculations from (1) cumulative fluid
inputs and outputs and (2) changes in measured body weight.49-55,57-72 The weight change method
has certain advantages because it accounts for unmeasured insensible losses, does not require an
invasive bladder catheter, and is less resource intensive. A weight-change method is preferred in
neonates to estimate fluid balance.58,73-77
Sick children are a heterogenous cohort of patients, and fluid overload may vary according to
patient-specific susceptibilities (eg, by patient age, case-mix, phase, or severity of illness). Thus, no
specific threshold can be recommended uniformly to define fluid overload in sick children.
Interventions to mitigate or treat fluid overload will need to be patient-specific and consider the
pathophysiologic context, the dynamics of the patient’s fluid balance, and the degree to which fluid
balance affects the severity of the patient’s fluid overload or volume depletion. eFigure 2 in the
Supplement provides a visual model of this precision approach (eBox and eBackground in the
Supplement).
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Workgroup 4: How Can Use of Kidney Support and Extracorporeal Therapies
in Children Be Advanced?
Consensus Statement 4A (Recommendation)
• A dedicated multidisciplinary team made up of kidney health care workers, patients, and families
along with institutional investments of personnel, time, materials, and quality assurance/
improvement systems are essential to a pediatric acute kidney support therapy (paKST) program.
Consensus Statement 4B (Suggestion)
• Patient-centered goals of care, degree of kidney recovery, physiological stability, fluid balance, and
global recovery and rehabilitation priorities inform decisions for de-escalation, liberation, transition,
and follow-up to optimize hospital-based and lifelong outcomes.
A paKST program requires thoughtful planning and synchronization across the health care enterprise
(eFigure 3 in the Supplement).28,78 Program development begins by identification of key
stakeholders with a vested interest in paKST delivery and outcomes. A multidisciplinary team of
kidney health care workers is responsible for fostering a culture of safety and transparency,
navigating organizational barriers, facilitating shared decision-making, providing education,
maintaining equipment, developing and maintaining policies, procedures, and guidelines, and
managing quality improvement data.28,78-84 Patients and families are vital partners, identifying goals
and advocating for effective and safe care. paKST device manufacturers and suppliers play an
important role in working with pediatric paKST providers to design products that can be used safely
and effectively in children, and to respond to the unique needs of a pediatric program. The care
delivery model should be based on available resources with representation from multiple
disciplines.28,78,79,82 Multiple blood purification and extracorporeal treatment modalities have been
developed (eTable 2 in the Supplement). Programs must define their standards of high-quality
delivery for the procedures they provide. Most quality metrics proposed by the ADQI XXII conference
are relevant for children.85 If a program is unable to provide high-quality care in a particular area, the
team must develop criteria and processes for transfer to an institution that provides such care, and
should examine the components lacking in their program to see if they can be addressed. The
education curriculum encompasses patient and team learning, is tailored to fit specific roles, and
includes competency assessments.28,78,80,86,87 Quality assurance or improvement systems should
be integrated into clinical practice, recognizing that cost, varied definitions, and lack of agreed-on
benchmarks are known barriers to implementation.28,78-80,82-84,88-92 Previous work by Rewa
et al80,89,90 and the 22nd ADQI conference28,80 has provided minimum programmatic standards
that may be used for paKST.
While most children who require paKST for AKI will achieve liberation from dialysis, there is
scant data to guide clinicians during kidney recovery.14,93-95 Current practices use estimates of the
ability to maintain euvolemia and metabolic balance for decisions about timing of paKST liberation,
transition, or de-escalation. Inability to execute timely transition from continuous paKST may
negatively affect outcomes, especially in light of emerging data on effectiveness of the ICU Liberation
Bundle.96-98 After paKST liberation, children are at risk for lifelong morbidity, including chronic
kidney disease, but guidance on optimal follow-up practices is lacking (eBox and eBackground in the
Supplement).3,99-101

Workgroup 5: How Do the Unique Pathobiology, Nutrition, and Pharmacology
of the Developing Child and AKI Need to Be Integrated?
Consensus Statement 5A (Recommendation)
• Successful pediatric translational AKI research programs include diverse teams using reverse
translational approaches in partnership with clinical and epidemiological findings that prioritize
development as a biologic variable. Sufficient support including pediatric specific government and
industry funding along with meaningful partnerships among health professionals is necessary to
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understand and leverage the unique aspects of pediatric AKI to address kidney health and disease
across the life course.
Consensus Statement 5B (Recommendation)
• Patient centered outcomes such as functional status, quality of life, and optimal growth and
development must drive the targeted nutritional interventions, optimizing short- and long-term
nutrition, and incorporate measures of acute and chronic changes of anthropometrics, body
composition, physical function, and metabolic control.
Engagement of diverse stakeholders across the preclinical and translational research realms is
needed to disseminate findings and transform care. Most translational AKI models do not account for
the additional complexity of pediatric AKI including the concept of development as a biologic variable
(DABV).102 The association between premature birth and kidney function and maturation remain
incompletely understood.103 Furthermore, the associations between a single AKI episode during
kidney development and short-term and long-term outcomes remain unclear.104 Potential sex
differences in AKI have prevented the inclusion of both males and females together in preclinical
animal studies. In pediatrics, sex as a biologic variable is further confounded by DABV; hormone
levels change throughout pubertal stages, and few clinical studies capture this information.105
Animal models of AKI that consider sex hormones and sex chromosomes could inform clinical
evaluations sensitive to sex as a biologic variable and DABV. The association between AKI and chronic
kidney disease has been established, however, there is a paucity of data on the systemic long-term
impact of AKI.106,107 The potential associations between AKI with respect to DABV and long-term
outcomes are unknown. Opportunities remain to use the unique aspects of pediatric patients,
including but not limited to the lack of chronic comorbidities and ability to understand the impact of
nephron endowment prior to nephron loss (Figure 231).
Malnutrition and protein energy wasting are prevalent and independently associated with
mortality in children hospitalized with AKI, especially those requiring paKST, with prevalence ranging
from 30% to 55%.108-111 Mortality is a crude end point to assess the importance of nutrition support
in children with AKI. AKI survivors are at risk of worsened functional status, chronic ventilation, or
dialysis after hospital discharge.111 Nutrition support and mobilization offer opportunities to improve
functional outcomes in survivors through attenuation of muscle loss and promotion of muscle
protein synthesis in critically ill children.112 The outcomes of malnutrition associated with somatic

Figure 2. Development as a Biologic Variable Related to Acute Kidney Injury
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growth, body composition, development, immune function, metabolic derangements, and longterm physical and neurocognitive functioning require more precise measurement tools and
targets.113 Nutritional therapeutic interventions are nuanced and include changes in feeding
modality, composition (macronutrient or micronutrient) and volume of nutrition-related fluids which
intersects with medical AKI management and metabolic control, which can be further complicated
by institution of paKST. Nutritional needs are further affected by DABV.
Identifying and measuring appropriate outcome variables represent the first step to define the
phenotypic nutritional morbidities in pediatric AKI, and thereby enable evaluation of nutritional
intervention efficacy.114,115 We recommend program-based focused nutrition support for children
with AKI and transitioning through acute kidney disease.116 Such a program would use evidencebased nutrition therapy adjusted in response to changes in objectively measured nutrition-related
outcomes characterized by mitigating functional decline, a return to metabolic homeostasis, and
facilitation of long-term physical and neurocognitive rehabilitative processes.
Physiologic derangement in acute illness, with susceptibility factors of DABV render kidneyeliminated and nephrotoxic medication use uniquely complex in sick children. High-value
medications can be selected for detailed pharmacokinetic/pharmacodynamic/pharmaco-omics
characterization to inform drug disposition, dosing, and monitoring decisions at the bedside for AKI
and paKST (eBox and eBackground in the Supplement).117,118

Workgroup 6: Who Are the Key Stakeholders and What Is Required to Promote
Education and Advocacy for AKI in Children?
Consensus Statement 6A (Recommendation)
• Given the adverse immediate and lifelong outcomes for children with AKI, education and advocacy
are essential, starting with the patient and family and expanding across health care teams, systems,
and communities.
Consensus Statement 6B (Suggestion)
• Customized AKI education and advocacy require a comprehensive, multidisciplinary, and patient/
family centered focus, with AKI champions embedded at every level, embracing the complexities
of diverse settings and individuals, which need to evolve over the pediatric life span.
Education may address the widespread gaps in AKI recognition.119 Lack of AKI awareness may be
associated with disparities in AKI outcomes.120 Extending education to all stakeholders can reduce
the risk of missing AKI or delaying care.121 Because delayed changes in clinical markers (serum
creatinine level, urine output) may delay recognition of kidney injury, education requires awareness
of risk factors. Education must be delivered in varied settings, different backgrounds of health care
workers, and available resources with a flexible approach adjusted for the scenario and depth of
knowledge needed (Figure 331).
Education must include recognition of AKI risk, prevention and treatment of volume depletion,
careful attention to fluid balance, avoidance or limitation of nephrotoxic medications, and blood
pressure monitoring. Checklists, standardized screening and care protocols (care bundles), adapted
to and used across varied settings, can enhance identification of patients with or at risk for AKI.122
Successful education programs also require strong advocacy efforts to engage different constituents,
including patients and families, community members, physicians, allied health care professionals,
industry affiliates, and governmental and nongovernmental organizations (eTable 3 in the
Supplement). Education must be tailored to all members of the health care team, including patients
and family, and should occur on micro (individual learners, training program curriculum, teaching
modules, and alert systems for providers) and macro (health care system, communitywide
educational programs, and governmental policy) levels.
AKI education must be an integral part of the curriculum of foundational and advanced
education for all health care professionals, with continuing medical education for all practitioners.
Programs should view AKI as a core competency metric.121,123 Specialists in AKI (including educators,
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researchers, and advocates) must use educational methods for those who access online free openaccess medical education,124 available globally 24 hours per day. Patients and families may be
unaware of the AKI episode or of the potential for long-term adverse outcomes. AKI education may
help empower them to participate in healthy lifestyle modification and may improve follow-up,
which has the potential to improve long-term outcomes.125,126 Adaptable and multifaceted
educational tools, available in a variety of primary languages and for varying levels of health literacy,
should support comprehensive care from admission through discharge, follow-up and potentially,
readmission. Connectivity between patient and family with clinician may be essential in the AKI care
continuum.
AKI diagnosis remains a significant challenge across areas with varying resource availability
(low-income, war zones, and disaster areas), with the lack of appropriate laboratory supplies,
adequate medical infrastructure, and personnel. A recent survey emphasized the importance of

Figure 3. The Role of Education and Advocacy in Pediatric Acute Kidney Injury (AKI)
Education
Risk mitigation
Recognition and care
Guidelines

Science and
government
Health care
systems
Community

Child and
family
Implementation

Awareness

Equitable access to
diagnostics

Networks

Kidney protective care
across the lifespan

Metrics of kidney health

Integrated
collaborative care

Risk stratification

Technological innovation to
remove barriers

Advocacy

Education to improve AKI awareness and recognition in children rests on the pillar of
advocacy and must engage key stakeholders in developing multidisciplinary contextappropriate customized approaches to improve AKI care globally and across all resource
settings. Effective AKI education programs center the child and family, and expand
across health care teams, systems, and communities with champions embedded at every
level, health care systems, science, and government. AKI education must be a core
competency for health care clinicians to ensure that AKI risk mitigation measures are in
place to reduce AKI in community and hospital settings, to facilitate early recognition of

AKI through technological innovation, and to appropriately manage AKI using contextspecific guidelines that recognize the need for continuity of care and clinical follow-up.
Implementation of an effective AKI education and advocacy program assures equitable
access to diagnostics, emphasizes integrated multidisciplinary collaborative care, and
recognizes the unique long-term health outcomes of AKI in children across the life span.
Adapted from the 26th Acute Disease Quality Initiative31 with permission. These are
open access images distributed under the terms of the Creative Commons
Attribution License.
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involving and educating governments about the implications of AKI.127 Fostering partnerships with
industry and the international medical community will also be beneficial. Public-private partnerships
and programs may have established platforms that can be used for earlier diagnosis of AKI (eBox and
eBackground in the Supplement).128

Discussion
The pADQI consensus statements are expert-derived landscape definitions of the multifaceted and
multidisciplinary approach needed to improve prediction, diagnosis, management, and follow-up
care for AKI in children. The AKI story requires partnerships between patients and providers, across
the medical landscape and across the ages of children. We have provided recommendations for
current efforts and identified opportunities to address knowledge gaps (eBox in the Supplement).

Limitations
This study has limitations. The recommendations of the pADQI are based on existing evidence and
consensus but a systematic review on all individual studies and pieces of data was not performed. We
also acknowledge recent studies on AKI epidemiology, biomarkers, fluid accumulation, kidney
support therapy, nutrition, pharmacology, and education are in progress or have been completed
since the completion of pADQI and we could not account for their findings in our recommendations.

Conclusions
Nearly 2 decades of work in critical care nephrology has delivered a robust foundation on which to
frame future AKI education, advocacy, research, and clinical practice. AKI in children is unique and is
associated with long-lasting consequences. Improved outcomes in patients will require a
comprehensive and cross-discipline approach requiring stakeholders across medicine, community,
and government to partner with children and their families.
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